Media

MARKETWATCH: Shares of Elicio Therapeutics were trading higher on the Nasdaq Friday, following the combination of the company with Angion Biomedica.

LABIOTECH: Elicio Therapeutics specializes in immunotherapeutic research in the field of cancer and infectious diseases. And its amphiphile technology (AMP) platform is the foundation for the various vaccine candidates in its pipeline, against cancer and other diseases. 

PHARMA'S ALMANAC: I’ve seen two areas within oncology in particular that have grown significantly with revolutionary potential in the coming year: therapeutics targeting KRAS mutations and the re-emergence of cancer vaccines. Christopher Haqq, MD, PhD

MED CITY NEWS: Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.

BUSINESS OF BIOTECH PODCAST: Chief Scientific Officer Peter DeMuth, PhD at Elicio HQ in Boston talks about how the platform works, and how it's driving rapid clinical progress for the company's robust pipeline of therapeutic vaccines in oncology.

Research Square, Dasari, et. al.

NPJ Vaccines - 2022
Seenappa LM, Jakubowski A, Steinbuck MP, et al.

BIOSPACE: The advances in immuno-oncology and adaptive cell therapy that began about a decade ago, however, are enabling fresh, biology-driven approaches with the potential to bring therapeutic cancer vaccines much closer to fruition.

PRECISION ONCOLOGY NEWS: Elicio Therapeutics said Tuesday that it received a $2.8 million grant from the Gastro-Intestinal Research Foundation (GIRF) in Chicago to fund research for two therapeutic cancer vaccines.

Scientific Translational Medicine, Hartwell, et. al.